drugset / Trial / NCT00933530
A Clinical Study to Assess the Safety and Pharmacokinetics of SRT2104 in Normal Healthy Male Volunteers
RandomizedCrossoverSingle-blindBasic science
Summary
The purpose of this study is to determine the safety and tolerability of SRT2104 (0.03, 0.1, 0.25, 0.5, 1.0, 2.0, and 3.0 g/day) in healthy male volunteers when administered after a single dose and once daily for 7 consecutive days. The purpose is also to characterize the pharmacokinetic profile of SRT2104 (0.03, 0.1, 0.25, 0.5, 1.0, 2.0, and 3.0 g/day) after a single dose and multiple administrations in healthy male volunteers.
Timeline
- Start
- 2008-05
- Primary completion
- 2008-11
- Completion
- 2008-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | SRT2104 | Small molecule | 0.01 g | Oral |
| Subject | SRT2104 | Small molecule | 0.03 g | Oral |
| Subject | SRT2104 | Small molecule | 0.1 g | Oral |
| Subject | SRT2104 | Small molecule | 0.25 g | Oral |
| Subject | SRT2104 | Small molecule | 0.5 g | Oral |
| Subject | SRT2104 | Small molecule | 1 g | Oral |
| Subject | SRT2104 | Small molecule | 2 g | Oral |
| Subject | SRT2104 | Small molecule | 3 g | Oral |